Zusammenfassung
Bisher standen lediglich Acetylcholinesterasehemmer wie z. B. Neostigmin zur Antagonisierung neuromuskulärer Restblockaden zur Verfügung. Mit dem modifizierten γ-Zyklodextrin Sugammadex gibt es zumindest für aminosteroidale Muskelrelaxanzien zukünftig eine Alternative. Es handelt sich bei dieser Substanz um eine ringförmige Zuckerverbindung, die eine stabile Einschlussverbindung mit aminosteroidalen Muskelrelaxanzien, insbesondere Rocuronium und Vecuronium, bildet. Dieser Wirkmechanismus unterscheidet sich somit grundsätzlich von dem der Acetylcholinesterasehemmer. Die nachfolgende Übersichtsarbeit fasst die bisherigen Untersuchungen im Rahmen des Zulassungsverfahrens zusammen. Insbesondere wird auf die Wirksamkeit, Nebenwirkungen und neue anästhesiologische Konzepte, die durch Sugammadex möglich sind, eingegangen.
Abstract
Up to now only acetylcholine esterase inhibitors, such as neostigmine, were available as antagonists of residual neuromuscular blocks. Sugammadex is a modified γ-cyclodextrin that binds rocuronium and chemically similar aminosteroidal muscle relaxants, such as vecuronium. The underlying mechanism of action is new and differs completely from that of acetylcholine esterase inhibitors. This review summarizes data published so far within the framework of the licensing procedure about the efficacy, safety and side-effects of sugammadex and presents potential new anesthesiological concepts using this compound.
Literatur
Alvarez-Gomez JA, Wattwil M, Vanacker B et al. (2007) Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur J Anaesthesiol 24: 124–125
Amao R, Zornow MH, McTaggart-Cowan R et al. (2007) Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 107: A1582
Arain SR, Kern S, Ficke DJ, Ebert TJ (2005) Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand 49: 312–315
Baillard C, Clec’h C, Catineau J et al. (2005) Postoperative residual neuromuscular block: a survey of management. Br J Anaesth 95: 622–626
Blobner M, Eriksson L, Scholz J et al. (2007) Sugammadex (2 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular block compared with neostigmine (50 μg/kg). Eur J Anaesthesiol 24: 124
Boer HD de, Egmond J van, Pol F van de et al. (2006) Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized rhesus monkeys. Br J Anaesth 96: 201–206
Boer HD de, Egmond J van, Pol F van de et al. (2006) Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology 104: 718–723
Boer HD de, Egmond J van, Pol F van de et al. (2006) Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized rhesus monkey. Br J Anaesth 96: 473–479
Boer HD de, Egmond J van, Pol F van de et al. (2006) Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 97: 681–686
Boer HD de, Driessen JJ, Marcus MA et al. (2007) Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 107: 239–244
Boer HD de, Driessen JJ, van Egmond J, Booij LH (2008) Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Can J Anaesth 55: 124–125
Bom A, Bradley M, Cameron K et al. (2002) A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem 114: 276–280
Broek L van den, Proost JH, Wierda JM (1994) Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol Suppl 9: 128–132
Capron F, Alla F, Hottier C et al. (2004) Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9. Anesthesiology 100: 1119–1124
Dahl V, Pendeville PE, Hollman MW et al. (2007) Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology 107: A1581
Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3: 1023–1035
Kam PJ de, Kuijk J van, Smeets JM et al. (2007) Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 107: A1580
Decoopman M, Cammu G, Suy K et al. (2007) Reversal of pancuronium-induced block by the selective relaxant binding agent sugammadex. Eur J Anaesthesiol 24: 110
Donati F (2007) Sugammadex: an opportunity for more thinking or more cookbook medicine? Can J Anaesth 54: 689–695
Duvaldestin P, Kuizenga K, Kjaer CC et al. (2007) Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose-response study. Eur J Anaesthesiol 24: 123
Eikermann M, Groeben H, Husing J, Peters J (2004) Predictive value of mechanomyography and accelerometry for pulmonary function in partially paralyzed volunteers. Acta Anaesthesiol Scand 48: 365–370
Eikermann M, Zaremba S, Malhotra A et al. (2008) Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 101: 344–349
Eleveld DJ, Kuizenga K, Proost JH, Wierda JM (2007) A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 104: 582–584
Epemolu O, Bom A, Hope F, Mason R (2003) Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 99: 632–637, discussion 636A
Epemolu O, Mayer I, Hope F et al. (2002) Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 16: 1946–1952
Fink H, Geldner G, Fuchs-Buder T et al. (2006) Muskelrelaxanzien in Deutschland 2005: Ein Vergleich zwischen den Anwendungsgewohnheiten in Krankenhäusern und Praxen. Anaesthesist 55: 668–678
Flockton E, Scanni E, Gomar C et al. (2007) Sugammadex after rocuronium provides faster recovery from neuromuscular blockade than neostigmine after cisatracurium. Eur J Anaesthesiol 24: 123
Fuchs-Buder T, Claudius C, Skovgaard LT et al. (2007) Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 51: 789–808
Fuchs-Buder T, Eikermann M (2006) Neuromuskuläre Restblockaden. Klinische Konsequenzen, Häufigkeit und Vermeidungsstrategien. Anaesthesist 55: 7–16
Gijsenbergh F, Ramael S, Houwing N, Iersel T van (2005) First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103: 695–703
Gordon M, Rex C, Ingimarsson J, Klarin B, Smeets J (2007) Pharamacokinetics of the selective relaxant binding agent sugammadex, administered for reversal of shalloow neuromuscular blockade induced by rocuronium or vecuronium. Eur J Anaesthesiol 24: 112
Groudine SB, Soto R, Lien C et al. (2007) A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 104: 555–562
Jones KR, Caldwell JE, Brull SJ, Soto R (2007) Faster reversal of profound rocuronium-induced neuromuscular blockade with sugammadex vs neostigmine. Anesthesiology 107: A1577
Kopman AF (2007) Sugammadex-rocuronium dosing. Anesth Analg 105: 883–884; author reply 884
Kopman AF (2006) Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 104: 631–633
Kopman AF, Chin W, Cyriac J (2005) Acceleromyography vs. electromyography: an ipsilateral comparison of the indirectly evoked neuromuscular response to train-of-four stimulation. Acta Anaesthesiol Scand 49: 316–322
Kopman AF, Zhaku B, Lai KS (2003) The „intubating dose“ of succinylcholine: the effect of decreasing doses on recovery time. Anesthesiology 99: 1050–1054
Lee C, Jahr JS, Candiotti K et al. (2007) Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology 107: A988
Lemmens HJM, El-Orbany MI, Berry J, Martin G (2007) Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology 107: A158
Lysakowski C, Suppan L, Czarnetzki C et al. (2007) Impact of the intubation model on the efficacy of rocuronium during rapid sequence intubation: systematic review of randomized trials. Acta Anaesthesiol Scand 51: 848–857
Maybauer DM, Geldner G, Blobner M et al. (2007) Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia 62: 12–17
McDonagh DL, Benedict PE, Kovac AL et al. (2007) Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology 107: A1583
Miller RD (2007) Sugammadex: an opportunity to change the practice of anesthesiology? Anesth Analg 104: 477–478
Molina AL, Boer HD de, Klimek M et al. (2007) Reversal of rocuronium-induced (1.2 mg kg−1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg−1). Br J Anaesth 98: 624–627
Naguib M (2007) Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 104: 575–581
Nigrovic V, Bhatt SB, Amann A (2007) Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant. J Pharmacokinet Pharmacodyn 34: 771–788
Paton WD, Waud DR (1967) The margin of safety of neuromuscular transmission. J Physiol 191: 59–90
Plaud B, Meretoja O, Pohl B et al. (2007) Reversal of rocuronium-induced neuromuscular blockade in paediatric and adult patients. Eur J Anaesthesiol 24: 124
Plaud B, Heumen E van, Zwiers A (2008) Sugammadex is well tolerated for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in a pooled analysis of adverse events in 10 placebo-controlled trials. Eur J Anaesthesiol 25: 9AP3–3
Proost JH, Eriksson LI, Mirakhur RK et al. (2000) Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 85: 717–723
Pühringer FK, Blaszyk M, Cammu G et al. (2007) Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium or vecuronium: dose-response studies. Eur J Anaesthesiol 24: 111
Puhringer FK, Heier T, Dodgson M et al. (2002) Double-blind comparison of the variability in spontaneous recovery of cisatracurium- and vecuronium-induced neuromuscular block in adult and elderly patients. Acta Anaesthesiol Scand 46: 364–371
Puhringer FK, Rex C, Sielenkamper AW et al. (2008) Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 109: 188–197
Roy JJ, Donati F, Boismenu D, Varin F (2002) Concentration-effect relation of succinylcholine chloride during propofol anesthesia. Anesthesiology 97: 1082–1092
Sacan O, White PF, Tufanogullari B, Klein K (2007) Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 104: 569–574
Shields M, Giovannelli M, Mirakhur RK et al. (2006) Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 96: 36–43
Sorgenfrei IF, Norrild K, Larsen PB et al. (2006) Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 104: 667–674
Sparr HJ (2002) Cyclodextrine. Ein neues Konzept zur Antagonisierung von Muskelrelaxanzien. Anaesthesist 51: 929–930
Sparr HJ, Vermeyen KM, Beaufort AM et al. (2007) Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology 106: 935–943
Staals LM, Snoeck MM, Driessen JJ et al. (2008) Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth (in press)
Suy K, Morias K, Cammu G et al. (2007) Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 106: 283–288
U.S. Food and Drug Administration (2008) Sugammadex – New Drug Application (NDA) 22–225: Industry presentation of Organon USA Inc. at the meeting of Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) of the Food and Food Drug Administration (FDA), March 11 2008. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008–4346s1–01-Schering-Plough-corebackup.pdf
U.S. Food and Drug Administration (2008) Sugammadex – New Drug Application (NDA) 22–225: FDA presentation at the meeting of Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) of the Food and Food Drug Administration (FDA), March 11 2008. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4346s1-02-FDA-corepresentation.ppt#289,1,SUGAMMADEX (SDX) Preliminary Efficacy Findings
Vanacker BF, Vermeyen KM, Struys MM et al. (2007) Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 104: 563–568
Viby-Mogensen J, Engbaek J, Eriksson LI et al. (1996) Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 40: 59–74
Interessenkonflikt
Doz. Sparr und Prof. Booij waren als Prüfärzte bei einigen der beschriebenen Zulassungsstudien von Sugammadex involviert. Doz. Sparr und Prof. Fuchs-Buder erhielten in der Vergangenheit Vortragshonorare von der Fa. Organon. Die Autoren versichern, dass die Präsentation des Themas unabhängig und die Darstellung der Inhalte neutral ist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sparr, H., Booij, L. & Fuchs-Buder, T. Sugammadex. Anaesthesist 58, 66–80 (2009). https://doi.org/10.1007/s00101-008-1455-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00101-008-1455-2